Unbiased AI-powered news
2 stories related to this topic, newest first.
benzinga.comNew results for Revolution Medicines' daraxonrasib were presented at the ASCO conference over the weekend. A pancreatic cancer expert described an emotional reaction after treating patients with the data.
Data released Sunday showed ivonescimab reduced death risk by 34 percent versus a PD-1 drug plus chemotherapy. The results are being presented at the ASCO meeting.